(UroToday.com) The third and final session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on molecular characterization of both tissue and blood, with a focus on implications for treatment with PARP inhibitors and beyond. In the final talk of this session, Dr. Eric Small discussed the role of both novel and proven treatment options in advanced prostate cancer and how we may best utilize these in treatment sequencing.